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Similar to other industrialized countries, Germany’s population is
ageing. Whereas some people enjoy good physical and cognitive
health into old age, others suffer from a multitude of age-related
disorders and impairments which reduce life expectancy and affect
quality of life. To identify and characterize the factors associated
with ‘healthy’ vs. ‘unhealthy’ ageing, we have launched the Berlin
Aging Study II (BASE-II), a multidisciplinary and multi-
institutional project that ascertains a large number of ageing-related
variables from a wide range of different functional domains.
Phenotypic assessments include factors related to geriatrics and in-
ternal medicine, immunology, genetics, psychology, sociology and
economics. Baseline recruitment of the BASE-II cohort was recently
completed and has led to the sampling of 1600 older adults (age
range 60–80 years), as well as 600 younger adults (20–35 years)
serving as the basic population for in-depth analyses. BASE-II data
are linked to the German Socio-Economic Panel Study (SOEP), a
long-running panel survey representative of the German population,
to estimate sample selectivity. A major goal of BASE-II is to facili-
tate collaboration with other research groups by freely sharing rele-
vant phenotypic and genotypic data with qualified outside
investigators.
Why was the cohort set up?
Similar to other industrialized countries, Germany’s
population is ageing. In 2009, nearly 26% of
Germans were aged over 60 years and approximately
19% were aged 18 years or younger.1 Recent projec-
tions suggest that this imbalance will increase by
2050 when nearly 15% of Germans will be 80 years
of age or older.1 Whereas some individuals enjoy good
physical and cognitive health into old age, others
suffer from a multitude of age-related disorders and
impairments which not only significantly reduce life
expectancy but also severely reduce quality of life and
y A full list of BASE-II collaborators and their affiliations can
be found at the end of the manuscript.
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increase health care costs. For more than 20 years,
our research group has been interested in identifying
factors which distinguish ‘healthy’ from ‘unhealthy’
ageing. To this end, members of the group initiated
the Berlin Aging Study (BASE) in 1988, a multidis-
ciplinary investigation of residents of former West
Berlin aged 70 to 100þ years. Between 1990 and
1993, 516 individuals were recruited into the core
sample of BASE and broadly examined regarding
their mental and physical health, psychological func-
tioning and social as well as economic status. Since
then, the study has been continued longitudinally,
and surviving participants have been reexamined up
to eight times.2,3 References 4 and 5 highlight some of
the scientific contributions of BASE to ageing re-
search. Despite its accomplishments, BASE suffered
from several shortcomings such as small sample
size, minimal collection of biological specimens from
study participants and a comparatively limited array
of health-relevant phenotypic assessments.
To overcome these limitations, we have launched
and recently completed baseline recruitment of a
second cohort, the Berlin Aging Study II (BASE-II),
which comprises 2200 adult volunteers from the
Berlin metropolitan area (Table 1). Even more so
than its predecessor, BASE-II is a multidisciplinary
project aimed at the identification and characteriza-
tion of factors associated with ‘healthy’ vs ‘unhealthy’
ageing. BASE-II includes a multidisciplinary and
multi-institutional ascertainment protocol that re-
cords a large number of variables from a wide range
of different domains for each participant (Figure 1).
Table 1 Selection of sociodemographic characteristics of the BASE-II cohort and comparison with representative samples
from Berlin and Germany
Characteristics
Young Old
(Age 20-35 years) (Age 60þ years)
BASE-II Berlin Germany BASE-II Berlin Germany
Number of observationsa 600 173 3802 1600 234 6487
Ageb 27.32 27.83 27.64 66.76 69.62** 70.51**
Female 0.50 0.55 0.53 0.50 0.50* 0.52
German nationality 0.99 0.96* 0.93** 0.99 0.96** 0.96*
Family status1
Married or living together 0.16 0.19 0.27** 0.57 0.65* 0.69**
Single 0.84 0.80 0.67** 0.09 0.06 0.03**
Divorced/separated 0 0.01 0.03** 0.29 0.14** 0.08**
Widowed 0 0 0 0.05 0.16** 0.19**
Highest school degree2
Elementary school 0.01 0.08** 0.17** 0.16 0.31** 0.54**
Intermediate school 0.12 0.21** 0.33** 0.27 0.36** 0.20**
High school 0.86 0.62** 0.42** 0.51 0.29** 0.18**
No school or other school 0.01 0.09** 0.08** 0.06 0.05 0.08**
Employment status
Employed 0.44 0.71** 0.72** 0.14 0.20** 0.16**
Self-rated health3
Very good 0.17 0.12 0.19 0.08 0.03** 0.03**
Good 0.29 0.49** 0.53** 0.32 0.26 0.25**
Fair 0.18 0.28** 0.21* 0.33 0.47** 0.43**
Poor or very poor 0.36 0.12** 0.07 0.28 0.24 0.29
Satisfaction with life in general4,c 7.01 7.06 7.12 7.49 6.83** 7.00**
Data sources: BASE-II, SOEP (V28), and unpublished data. All variables for BASE-II are derived from the full baseline cohort
(n¼ 2200), except where labelled with 1(n¼ 2155), 2(n¼ 2172), 3(n¼ 2188), 4(n¼ 2079).
aValues are presented as means for continuous variables and proportions for dichotomous variables.
bAge is calculated using 2009 as reference.
cAs measured on a Likert scale19 ranging from 0 (‘completely dissatisfied’) to 10 (‘completely satisfied’).
P-values are based on two-sample t-tests of proportions (for binary outcome variables) and two-sample mean comparison t-tests
(for continuous outcome variables) comparing BASE-II with SOEP data for Berlin and Germany (not overlapping with BASE-II):
*P-value4 0.05; **P-value4 0.01.












The assessments include factors related to geriatrics
and internal medicine, immunology, genetics, psych-
ology, sociology and economics (see legend of Table 2
for details).
Who is in the cohort?
Only residents of the greater metropolitan area of
Berlin, Germany, were eligible for participation in
BASE-II. Potential participants were drawn from a
pool of individuals originally recruited at the
Max-Planck-Institute for Human Development as
part of a number of earlier projects with a focus on
neurocognition (a detailed description of these pro-
jects can be found at: http://www.mpib-berlin.mpg.
de/sites/default/files/media/pdf/25/lip_report_11.pdf).
Briefly, participant recruitment for these and other
studies was based on advertisements in local news-
papers and the public commuter transport system.
This led to approximately 10 000 responders of
whom 2875 were invited for an additional screening
Figure 1 (a) Overall organizational structure of BASE-II and associated research teams. (b) Project subgroups of BASE-II
research teams. CRGG, Charite´ Geriatric Research Group; MPIMG, Max Planck Institute for Molecular Genetics; SOEP,
German Socio-Economic Panel Study; CMRT, Center for Medical Research Tu¨bingen; MPIHD, Max Planck Institute for
Human Development












(either in-house or by telephone), leading to 2262 in-
dividuals eligible for inclusion in BASE-II, i.e. 79% of
those who were initially invited. From these, we se-
lected 2200 individuals to represent the BASE-II base-
line cohort (Table 1) based on their age and sex as
follows. A total of 1600 participants were assigned to
an older subgroup aged between 60 and 80 years,
whereas the remaining 600 individuals were assigned
to a younger subgroup (serving as a reference popu-
lation) aged between 20 and 35 years. By design, each
age subgroup contains equal numbers of males and
females. See Table 1 for other socio-demographic de-
tails of the BASE-II baseline cohort.
Some ageing-related changes, such as decline in per-
ceptual speed, begin in early adulthood. At the same
time, recent longitudinal studies indicate that average
performance on other cognitive abilities, such as epi-
sodic memory, is relatively stable until about 60 years
of age, and starts declining thereafter.6 Hence, we
decided to start observing older adults at an age
where most would show subsequent decline on
most variables of interest.
Comparisons with representative survey data from
Berlin and Germany, ascertained via the SOEP ques-
tionnaire (see below), reveal that BASE-II participants
are characterized by higher education and better
self-reported health status than the general popula-
tion of Berlin and Germany (Table 1). In addition,
BASE-II participants in the older subgroup report a
significantly higher divorce/separation rate than




CRGG Anamnesis Medical and family history, lifestyle, medication
Questionnaires Physical activity, social aspects (Nikolaus), sexuality, nutrition,
hearing
Laboratory values 4100 laboratory values incl. oral glucose tolerance test and leucocyte
telomere length
Physical status and functional tests Tinetti Mobility Test, Timed ‘Up & Go’, Barthel Index, test of fine
motor skills, grip strength, anthropometric parameters
Psychological tests MMSE, Clock Completion Test, DemTect, GDS, CERAD plus
Other diagnostic tests BIA, DEXA, ECG, long-term ECG, audiometry, spirometry; motion
monitoring (belt)
CMRT Immunology PBMC surface marker determination by 14-colour flow cytometry;
in vitro assays for immune cell integrity; plasma cytokine and
chemokine quantification; presence and impact of common
herpesviruses
MPIHD Cognition Executive control; episodic memory; processing speed and variability;
risk and decision-making; fluid intelligence, reading abilities
Subjective health Questionnaires of subjective well-being and health
SOEP Economics Income; employment status
Sociology Social stratum
Political science Values; political preferences
Psychology Personality traits
Survey methodology Interviewer characteristics; geo-coding
MPIMG GWAS Microarray-based SNP genotyping; genome-wide association
analyses; imputation
Validation Targeted follow-up genotyping in independent cohorts; meta-analysis
Fine-mapping Identification of biochemically functional DNA variants, e.g. by direct
resequencing
Examples of the phenotypic and genotypic assessments performed in each BASE-II participant by the various research teams. For
many of the domains listed, more assessments will actually be performed; please contact the study coordinator for more details.
MMSE, Mini-Mental State Examination; GDS, Geriatric Depression Scale; CERAD, Consortium to Establish a Registry for
Alzheimer’s Disease; BIA, Bioelectrical Impedance Analysis; DEXA, dual energy X-ray absorptiometry; ECG, electrocardiogram.
aBASE-II research teams (see also Figure 1) and status of completion of full baseline assessments: CRGG (full assessments
completed in n¼ 1502 participants): Charite´ Geriatric Research Group (Main research topic: Internal medicine/geriatrics); CMRT
(n¼ 250 completed from a total of 1350 biobanked samples): Center for Medical Research Tu¨bingen (Immunology); MPIHD
(n¼ 2134 completed): Max Planck Institute for Human Development (Psychology & Project Coordination); SOEP (n¼ 1447 com-
pleted): German Socio-Economic Panel Study (Socio-economics and survey methodology); MPIMG (n¼ 1976 completed):
Max Planck Institute for Molecular Genetics (Genetics); GWAS: Genome-Wide Association Study.












participants in the age-matched reference popula-
tions. For convenience samples such as BASE-II this
is a commonly observed phenomenon.7
What has been measured?
Human ageing is a complex process affecting a large
number of correlated domains. Consequently, ageing
research requires multi-dimensional data collection as
well as extensive multi-disciplinary collaborations.
Both aspects are strongly emphasized in BASE-II
where we have assembled a multi-disciplinary re-
search team consisting of specialists in geriatrics, in-
ternal medicine, immunology, psychology, genetics,
sociology, and economics (Figure 1). A major chal-
lenge for studies dealing with ascertained research
cohorts is to systematically determine the degree
of sampling bias and to judge the extent to which
results can be generalized to the population as a
whole. To this end, selectivity and representativeness
of our sample is evaluated [via the German Socio-
Economic Panel Study (SOEP)] and—whenever ne-
cessary—accounted for by a team specialized in
survey methodology in the context of cohort studies.
The scope and breadth of our assessments makes
BASE-II unique in the field of human ageing re-
search. Below we provide brief overviews of the vari-
ous phenotypic domains examined in each participant
by the respective research teams (see also Table 2).
(i) Internal medicine/geriatrics (Charite´ Research
Group on Geriatrics; CRGG): In addition to pro-
viding an in-depth history of current and pre-
vious medical conditions, this branch of
BASE-II is performing an exhaustive medical
examination guided by an extensive array of
laboratory and functional tests. All tests and
examinations are part of a 2-day study protocol
designed to assess each individual’s objective
and subjective health status. In addition to re-
cording disease states, we also monitor do-
mains which are known to deteriorate with
normal ageing (e.g. grip strength, hearing,
vision, mobility, bone density), and determine
each participant’s activities of daily living, nu-
tritional habits, current and past use of medi-
cation, as well as self-rated health. Alongside
the medical assessments, each person under-
goes a neuropsychological screening for the
detection of dementia or mild cognitive impair-
ment [e.g. via the Mini-Mental State
Examination (MMSE), clock drawing test
and the early dementia screening test
(DemTect)]. Overall, we assess more than
4000 individual phenotypic variables in this
branch of BASE-II.
(ii) Immunology (Center for Medical Research,
University of Tu¨bingen; CMRT): The immuno-
logical assessments of BASE-II aim to
determine specific ‘immune risk profiles’
(IRPs) of each participant. The IRP concept is
tightly linked to the occurrence of immunose-
nescence, i.e. dysregulated or compromised im-
munity in the elderly, possibly modifying
susceptibility to a number of age-related dis-
eases.8 Determining an individual’s IRP entails
measuring—at each visit—a number of
immune parameters ex vivo, using peripheral
blood mononuclear cells (PBMC) derived from
whole-blood samples of each BASE-II partici-
pant. In addition we systematically determine
antibody titres for common viral antigens [e.g.
originating from infections with cytomegalo-
virus (CMV), herpes simplex virus (HSV) and
other herpes viruses] and measure plasma
levels of multiple cytokines and chemokines.
(iii) Psychology (Max Planck Institute for Human
Development; MPIHD): Adequate cognitive
functioning is a major prerequisite for many
aspects of ‘successful’ ageing and for preserving
a self-determined lifestyle. Hence, the psych-
ology branch of BASE-II performs a large
number of cognitive tests covering a compre-
hensive array of cognitive abilities. The 6-h as-
sessment protocol is divided into two sessions
of 3 h each and applies test batteries to evaluate
working memory, attention control, word and
object recall, fluid intelligence, verbal skills and
decision making, as well as risk-taking behav-
iour. Another focus is to explore subjective par-
ameters via the use of questionnaires. These
cover areas such as self-rated health and
well-being, coping and general attitudes to-
wards the ageing process.
(iv) Socio-economics and survey methodology
(German Socio-Economic Panel Study; SOEP):
All BASE-II participants are asked to complete
the SOEP questionnaire, which is applied to a
representative longitudinal survey of 20 000
adults in Germany.9 The questionnaire assesses
over 120 socio-economic and behavioural vari-
ables (such as marital status, income, self-rated
health, personal traits etc.), which have been
exhaustively tested for their validity and reli-
ability in the context of panel studies.10 In add-
ition, all BASE-II survey data are ‘geo-coded’,
i.e. each participant is assigned an almost exact
geographical coordinate according to the street
block of his/her residential address (Figure 2).11
In the context of BASE-II these data are used
to achieve two goals: First, SOEP data allow the
identification of and adjustment for potential
confounders in the phenotype/genotype assess-
ments of the other branches. Owing to the
availability of SOEP data for representative col-
lections of 1000 participants from Berlin (ran-
domly drawn and not included in BASE-II) and
20 000 individuals representative for all other












regions across Germany, we are also able to
systematically assess and adjust for ascertain-
ment bias in the BASE-II cohort. Secondly,
many SOEP items (e.g. subjective well-being,
risk aversion) are interesting phenotypic out-
come variables themselves and can be analysed
with data from the other domains (e.g.
genetics).
(v) Genetics (Max Planck Institute for Molecular
Genetics; MPIMG): Many of the phenotypes
measured in BASE-II are under ‘complex gen-
etic’ control. That is, a substantial fraction of
their phenotypic variance can be explained by
the effects of common DNA sequence variants
(‘polymorphisms’). To elucidate the impact of
genetics on the phenotypes assessed by the
other subprojects, each BASE-II participant is
subjected to microarray-based genome-wide
genotyping of single nucleotide polymorphisms
(SNPs) using the Genome-Wide Human SNP
Array 6.0 from Affymetrix Inc. (already com-
pleted in 90% of all participants).12 This
array directly measures approximately 900 000
SNP markers. Based on these data, we will be
able to infer genotypes at several million
untyped SNPs using recently developed imput-
ation strategies. Using currently available gen-
etic reference populations, we can impute
genotypes of up to 10 million additional SNP
markers for the actual association analyses.13
The most compelling signals will be validated
in data sets of up to 2000 independent individ-
uals followed by systematic fine-mapping to
identify the underlying functional DNA vari-
ants.14 Ultimately, this subproject will lead to
a comprehensive genome-wide ‘map’ of
Figure 2 Example of geo-coding in the BASE-II cohort. Each BASE-II participant’s address is first recoded to the coord-
inates of the centre of the home address street block and then mapped onto a local street map [provided by OpenStreetMap
(http://www.openstreetmap.org)]. For each coordinate, a wealth of auxiliary environmental information is available (such
as nearest distance to certain points of interest, climate, precipitation etc.) which can be incorporated in BASE-II specific
analyses. The large map in the centre of the figure indicates geo-coded BASE-II participants with SOEP data currently
available (n¼ 1447); the smaller map at the top left indicates the number of SOEP respondents living in Berlin not included
in BASE-II (n¼ 407; see also Table 1)












validated genetic loci with significant effects on
ageing-related phenotypes of relevance in
BASE-II and other cohorts.
What has it found to date? Key
findings and publications
At the time of writing (October 2012), in-depth exam-
inations have been completed in approximately
two-thirds or more (depending on the phenotypic
domain) of the 2200 baseline BASE-II participants
(see Table 2). This includes the microarray-based gen-
otyping allowing preliminary genome-wide associ-
ation analyses to be performed in this data set. In
the following paragraph, we will highlight the results
derived from BASE-II baseline data assessing the po-
tential impact of genetic polymorphisms in
brain-derived neurotrophic factor (BDNF) on cognitive
performance.
BDNF is a neurotrophin that plays an important role
in regulating activity-dependent synaptic plasticity,
which is essential in human memory functions. The
results summarized below and in Figure 3 are based
on investigations of the effect of a well-established
genetic polymorphism in the BDNF gene on episodic
memory performance. This polymorphism (rs6265)
leads to a substitution of one amino acid in the
BDNF protein (i.e. changing a valine [Val] to methio-
nine [Met] at codon 66; a.k.a. Val66Met) and appears
to control the neuronal secretion of BDNF in humans
in the sense that carriers of the Met allele show lower
levels of BDNF as compared with the Val allele.15 In
one of our analyses, we compared older and younger
BASE-II participants on backwards serial recall per-
formance. Serial recall memory typically yields a
U-shaped function, with better recall performance
for items at the beginning and at the end of a list.
We found a significant difference between Met- and
Val/Val-carriers in the sample of older adults, but not
in the sample of younger adults. These results, origin-
ally published in a subset of 948 BASE-II partici-
pants,16 have been followed up in the full BASE-II
cohort in individuals with genotype and phenotype
data available (n¼ 1570). The updated results con-
tinue to show an overall correlation between
memory performance and rs6265 Met-allele carrier
status (F¼ 4.56; P< 0.05). However, the age x
BDNF interaction was attenuated, now only showing
a statistical trend for the effect to be more pro-
nounced in older adults (P-value for age x BDNF
interaction¼ 0.1; Figure 3). These findings hint at
the possibility that some genetic effects may be
‘magnified’ with increasing age when brain and cog-
nitive resources become more limited,17 and empha-
size the need to assess both young and old adults in
projects aimed at elucidating ageing-related biological
effects.
What are the main strengths and
weaknesses?
As outlined above, we consider as major strengths of
BASE-II the following: (i) The study’s in-depth and
multi-disciplinary examination and analysis protocol
assessing a very large number of ageing-related
phenotypes from very diverse domains. These include
fields as diverse as psychology, molecular genetics,
immunology, economics, sociology and survey meth-
odology (Figure 1). Especially the survey data to-
gether with the detailed geo-coding (Figure 2) will
allow us to detect and account for selectivity and
other sources of bias with respect to the representa-
tiveness of our cohort. For instance, first comparisons
between BASE-II participants and representative
groups of older and younger adults in Berlin and
Germany show that people with a higher educational
background and those with a more positive outlook
on life are more willing to participate (see Table 1).
These findings suggest that weighting for these indi-
cators in the context of medical and psychological
surveys might be as important as in social scientific
research. (ii) In addition to providing a broad assess-
ment of phenotypic and genotypic variability asso-
ciated with human ageing, another strength of
BASE-II is the depth of its ascertainment with 2200
participants recruited at baseline. This sample size
provides excellent power to detect even small effect
sizes across a wide range of scenarios. For instance, in
the older subgroup alone (n¼ 1600) we are able to
detect genetic factors that explain down to 3% of
Figure 3 The impact of brain-derived neurotrophic factor
(BDNF) on cognitive performance. Average proportion of
items correctly recalled in a backward serial recall test
separated by age and BDNF polymorphism. A difference in
memory performance is observed between Met-carriers vs
Val/Val-carriers, with the latter showing better memory
performance. This effect appears to be slightly more pro-
nounced in the older subsample, although the age x inter-
action only showed a marginal effect (P¼ 0.1; n¼ 1570
participants, see text for more details)












the phenotypic variance of quantitative traits with
490% power at an alpha-level of 5 x 108, which
represents a common threshold to declare the
genome-wide significance of association findings.12
(iii) Additionally, all of the principal research teams
involved have a long-standing history of working to-
gether on related research projects. Furthermore,
three teams (geriatrics, psychology and social sci-
ences) were already involved in leading and complet-
ing BASE-II’s predecessor study (BASE, see above).
Collaboration across research groups will be greatly
facilitated by the fact that all but one of the partici-
pating centres are located in the city of Berlin.
Potential weaknesses of BASE-II include the follow-
ing. Owing to our heterogeneous ascertainment
scheme, some of the hypothesis-generating results
may be biased. Although this limitation can be ad-
dressed to a certain extent by adjustments
(weighting) based on representative SOEP survey
and geo-coded neighbourhood data, the possibility
of selection bias always remains. Of course, this is
not only true for every cohort study with non-random
recruitment schemes (like BASE-II), but also for all
studies based on voluntary participation. The latter is
the case for all surveys and creates selective non-
response. In addition, although the overall sample
size of BASE-II is sufficiently large to address many
research questions (see above), it is too small for
other areas. For instance, many age-related disorders
have prevalence rates <10% (e.g. Parkinson’s disease,
many age-related cancers), and can therefore not be
sufficiently studied in BASE-II. At the same time, the
scope of our multi-dimensional assessment and ana-
lysis protocol vastly increases the chances to identify
many of the major factors underlying age-associated
disorders and impairments. Hopefully in the not too
distant future the results of our project—in concert
with other related projects in Germany and else-
where—will help to develop efficient measures to de-
celerate or even prevent some of the most pressing
age-associated functional and social impairments.
Can I get hold of the data? Where
can I find out more?
More details about BASE-II can be found at a dedi-
cated website: http://www.base2.mpg.de. One of the
declared goals of BASE-II is to enable and facilitate
collaboration with other research laboratories.
Interested groups should contact our study coordinator
(Dr Katrin Schaar; contact details are available from
the above website), for the data-sharing application
form. Each application will be reviewed by the
BASE-II Steering Committee (currently: L.B., U.L.,
G.P., E.St-T and G.G.W.) and the decision communi-
cated to the applicants usually within 4 weeks of sub-
mission. Currently, BASE-II data are already being
used in a number of collaborative research projects,
including but not limited to studies on the genetics
of multiple sclerosis (University of Mainz,
Germany)18 and coronary heart disease (University of
Schleswig Holstein, Lu¨beck, Germany), self-rated
health (as part of the GENEQOL consortium led by
the University of Amsterdam, the Netherlands) and
the genetics of cognitive phenotypes (University of
Southern California, USA).
Additional BASE-II investigators
Martin Becker,i Nina Bucholtz,ii Evelyna
Derhovanessian,iii Denis Gerstorff,iv Jan Goebel,v
Hauke Heekeren,i,vi Martin Kroh,v Tian Liu,i,vii
Wilfried Nietfeld,vii Martin Lo¨vde´n,i,viii,ix Ludmila
Mu¨ller, Goran Papenberg,i,viii Katrin Schaar,i,ii
Brit-Maren M Schjeide,vii Florian Schmiedeki,v,x and
Julia Schro¨der,vii affiliated as follows:
iCenter for Lifespan Psychology, Max Planck
Institute for Human Development, Berlin, Germany,
iiCharite´ Research Group on Geriatrics, Charite´-
Universita¨tsmedizin, Berlin, Germany, iiiCenter for
Medical Research, University of Tu¨bingen, Tu¨bingen,
Germany, ivDepartment of Psychology, Humboldt
Universita¨t zu Berlin, Berlin, Germany, vGerman
Socio-Economic Panel Study (SOEP), Deutsches
Institut fu¨r Wirtschaftsforschung, Berlin, Germany,
viDepartment of Education and Psychology, Free
University, Berlin, Germany, viiDepartment of
Vertebrate Genomics, Max Planck Institute for
Molecular Genetics, Berlin, Germany, viiiAging
Research Center, Karolinska Institutet, Stockholm,
Sweden, ixDepartment of Psychology, Lund
University, Lund, Sweden and xGerman Institute for
International Educational Research (DIPF), Frankfurt
am Main, Germany.
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KEY MESSAGES
 BASE-II is a multi-disciplinary project aimed at identifying and characterizing factors associated with
‘healthy’ and ‘unhealthy’ ageing in 2200 adults from Berlin, Germany.
 Comparing BASE-II data with those from participants of the representative German Socio-Economic
Panel Study (SOEP) showed a significant overrepresentation of persons with higher education and
those with a higher life satisfaction.
 Overrepresentation of certain groups is relatively common in self-recruiting studies (convenience
samples) and emphasizes the need to adjust for such non-demographic indicators, which is made
possible for each BASE-II participant owing to the availability of representative SOEP data.
 Correlating memory performance with a common non-synonymous polymorphism (rs6265) in the
gene encoding brain-derived neurotrophic factor (BDNF) revealed significantly better memory per-
formance in carriers who were homozygous for the valine allele as compared with the remainder of
the sample.
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